Dose response with onabotulinumtoxinA for post‐stroke spasticity: A pooled data analysis
Identifieur interne : 001689 ( Main/Exploration ); précédent : 001688; suivant : 001690Dose response with onabotulinumtoxinA for post‐stroke spasticity: A pooled data analysis
Auteurs : Stuart A. Yablon [États-Unis] ; Mitchell F. Brin [États-Unis] ; Amanda M. Vandenburgh [États-Unis] ; Jihao Zhou [États-Unis] ; Susan M. Garabedian-Ruffalo [États-Unis] ; Susan Abu-Shakra [États-Unis] ; Frederick C. Beddingfield Iii [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-02-01.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Ashworth Scale, Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (therapeutic use), Clinical Trials as Topic, Data analysis, Dose-Response Relationship, Drug, Humans, Muscle Spasticity (etiology), Muscle Spasticity (therapy), Nervous system diseases, Spasticity, Stroke, Stroke (complications), Treatment Outcome, dose response, onabotulinumtoxinA, spasticity.
- MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A.
- chemical , therapeutic use : Botulinum Toxins, Type A.
- complications : Stroke.
- etiology : Muscle Spasticity.
- therapy : Muscle Spasticity.
- Clinical Trials as Topic, Dose-Response Relationship, Drug, Humans, Treatment Outcome.
Abstract
Clinical trials demonstrate that onabotulinumtoxinA reduces upper limb post‐stroke spasticity, with therapeutic response influenced by injected dose. Individual studies provide limited insight regarding muscle group‐specific dose–response relationships. Our objective was to characterize dose–response relationships between onabotulinumtoxinA and muscle tone in specific upper limb muscles. Individual patient data from seven multicenter, randomized, double‐blind, placebo‐controlled trials were pooled. Of 544 post‐stroke patients enrolled, 362 received onabotulinumtoxinA and 182 received placebo, injected into the flexor carpi radialis (FCR), flexor carpi ulnaris (FCU), flexor digitorum superficialis (FDS), flexor digitorum profundus (FDP), and/or biceps brachii (BB). Ashworth Scale score change at week 6 (AshworthCBL) was the primary outcome measure for muscle tone. For a broader analysis of response, AshworthCBL/onabotulinumtoxinA dosage relationships were characterized using three techniques: (1) AshworthCBL plotted as a function of onabotulinumtoxinA dose in Units (U) [dose–response curve]; (2) mean AshworthCBL per onabotulinumtoxinA dose depicting the responses seen with specific dose injection clusters/groups for each specific muscle group; and (3) onabotulinumtoxinA dose estimated to produce a mean 1‐point decrease in AshworthCBL as an indicator of clinically meaningful benefit of treatment. Increasing onabotulinumtoxinA doses produced greater AshworthCBLs (muscle tone improvements). The maximal week 6 response (Emax) model indicated a saturating dose–response relationship, with mean Emax AshworthCBL values of ‐1.48, ‐1.48, ‐0.63, ‐0.77, and ‐0.61 in the FCR, FCU, FDS, FDP, and BB, respectively. OnabotulinumtoxinA doses estimated to produce a mean 1‐point decrease in AshworthCBL were: 22.5U, 18.4U, 66.3U, 42.5U in the FCR, FCU, FDS, and FDP, respectively, and not determinable in the BB. These analyses demonstrate a saturating effect of greater muscle tone improvements with increasing onabotulinumtoxinA doses in post‐stroke spasticity patients. These findings suggest potentially effective onabotulinumtoxinA doses in selected muscle groups in this study population. © 2010 Movement Disorder Society.
Url:
DOI: 10.1002/mds.23426
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000749
- to stream Istex, to step Curation: 000749
- to stream Istex, to step Checkpoint: 000422
- to stream PubMed, to step Corpus: 001506
- to stream PubMed, to step Curation: 001506
- to stream PubMed, to step Checkpoint: 001364
- to stream Ncbi, to step Merge: 002F11
- to stream Ncbi, to step Curation: 002F11
- to stream Ncbi, to step Checkpoint: 002F11
- to stream Main, to step Merge: 001743
- to stream PascalFrancis, to step Corpus: 000718
- to stream PascalFrancis, to step Curation: 002600
- to stream PascalFrancis, to step Checkpoint: 000623
- to stream Main, to step Merge: 001C13
- to stream Main, to step Curation: 001689
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dose response with onabotulinumtoxinA for post‐stroke spasticity: A pooled data analysis</title>
<author><name sortKey="Yablon, Stuart A" sort="Yablon, Stuart A" uniqKey="Yablon S" first="Stuart A." last="Yablon">Stuart A. Yablon</name>
</author>
<author><name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
</author>
<author><name sortKey="Vandenburgh, Amanda M" sort="Vandenburgh, Amanda M" uniqKey="Vandenburgh A" first="Amanda M." last="Vandenburgh">Amanda M. Vandenburgh</name>
</author>
<author><name sortKey="Zhou, Jihao" sort="Zhou, Jihao" uniqKey="Zhou J" first="Jihao" last="Zhou">Jihao Zhou</name>
</author>
<author><name sortKey="Garabedian Uffalo, Susan M" sort="Garabedian Uffalo, Susan M" uniqKey="Garabedian Uffalo S" first="Susan M." last="Garabedian-Ruffalo">Susan M. Garabedian-Ruffalo</name>
</author>
<author><name sortKey="Abu Hakra, Susan" sort="Abu Hakra, Susan" uniqKey="Abu Hakra S" first="Susan" last="Abu-Shakra">Susan Abu-Shakra</name>
</author>
<author><name sortKey="Beddingfield Iii, Frederick C" sort="Beddingfield Iii, Frederick C" uniqKey="Beddingfield Iii F" first="Frederick C." last="Beddingfield Iii">Frederick C. Beddingfield Iii</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1D12C53AFAFD0319789B7A043657DDB7B6BBBFA9</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23426</idno>
<idno type="url">https://api.istex.fr/document/1D12C53AFAFD0319789B7A043657DDB7B6BBBFA9/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000749</idno>
<idno type="wicri:Area/Istex/Curation">000749</idno>
<idno type="wicri:Area/Istex/Checkpoint">000422</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Yablon S:dose:response:with</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20960474</idno>
<idno type="wicri:Area/PubMed/Corpus">001506</idno>
<idno type="wicri:Area/PubMed/Curation">001506</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001364</idno>
<idno type="wicri:Area/Ncbi/Merge">002F11</idno>
<idno type="wicri:Area/Ncbi/Curation">002F11</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002F11</idno>
<idno type="wicri:Area/Main/Merge">001743</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0188446</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000718</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002600</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000623</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Yablon S:dose:response:with</idno>
<idno type="wicri:Area/Main/Merge">001C13</idno>
<idno type="wicri:Area/Main/Curation">001689</idno>
<idno type="wicri:Area/Main/Exploration">001689</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dose response with onabotulinumtoxinA for post‐stroke spasticity: A pooled data analysis</title>
<author><name sortKey="Yablon, Stuart A" sort="Yablon, Stuart A" uniqKey="Yablon S" first="Stuart A." last="Yablon">Stuart A. Yablon</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baylor Institute for Rehabilitation, Dallas, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global Clinical Development, Allergan, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of California, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vandenburgh, Amanda M" sort="Vandenburgh, Amanda M" uniqKey="Vandenburgh A" first="Amanda M." last="Vandenburgh">Amanda M. Vandenburgh</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global Clinical Development, Allergan, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhou, Jihao" sort="Zhou, Jihao" uniqKey="Zhou J" first="Jihao" last="Zhou">Jihao Zhou</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global Clinical Development, Allergan, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garabedian Uffalo, Susan M" sort="Garabedian Uffalo, Susan M" uniqKey="Garabedian Uffalo S" first="Susan M." last="Garabedian-Ruffalo">Susan M. Garabedian-Ruffalo</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Southern California, School of Pharmacy, Los Angeles, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Los Angeles</settlement>
</placeName>
<orgName type="university">Université de Californie du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Abu Hakra, Susan" sort="Abu Hakra, Susan" uniqKey="Abu Hakra S" first="Susan" last="Abu-Shakra">Susan Abu-Shakra</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global Clinical Development, Allergan, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Beddingfield Iii, Frederick C" sort="Beddingfield Iii, Frederick C" uniqKey="Beddingfield Iii F" first="Frederick C." last="Beddingfield Iii">Frederick C. Beddingfield Iii</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global Clinical Development, Allergan, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-02-01">2011-02-01</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="209">209</biblScope>
<biblScope unit="page" to="215">215</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1D12C53AFAFD0319789B7A043657DDB7B6BBBFA9</idno>
<idno type="DOI">10.1002/mds.23426</idno>
<idno type="ArticleID">MDS23426</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ashworth Scale</term>
<term>Botulinum Toxins, Type A (administration & dosage)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Clinical Trials as Topic</term>
<term>Data analysis</term>
<term>Dose-Response Relationship, Drug</term>
<term>Humans</term>
<term>Muscle Spasticity (etiology)</term>
<term>Muscle Spasticity (therapy)</term>
<term>Nervous system diseases</term>
<term>Spasticity</term>
<term>Stroke</term>
<term>Stroke (complications)</term>
<term>Treatment Outcome</term>
<term>dose response</term>
<term>onabotulinumtoxinA</term>
<term>spasticity</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Stroke</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Muscle Spasticity</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Muscle Spasticity</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Dose-Response Relationship, Drug</term>
<term>Humans</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Accident cérébrovasculaire</term>
<term>Analyse donnée</term>
<term>Hypertonie spastique</term>
<term>Pathologie du système nerveux</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Clinical trials demonstrate that onabotulinumtoxinA reduces upper limb post‐stroke spasticity, with therapeutic response influenced by injected dose. Individual studies provide limited insight regarding muscle group‐specific dose–response relationships. Our objective was to characterize dose–response relationships between onabotulinumtoxinA and muscle tone in specific upper limb muscles. Individual patient data from seven multicenter, randomized, double‐blind, placebo‐controlled trials were pooled. Of 544 post‐stroke patients enrolled, 362 received onabotulinumtoxinA and 182 received placebo, injected into the flexor carpi radialis (FCR), flexor carpi ulnaris (FCU), flexor digitorum superficialis (FDS), flexor digitorum profundus (FDP), and/or biceps brachii (BB). Ashworth Scale score change at week 6 (AshworthCBL) was the primary outcome measure for muscle tone. For a broader analysis of response, AshworthCBL/onabotulinumtoxinA dosage relationships were characterized using three techniques: (1) AshworthCBL plotted as a function of onabotulinumtoxinA dose in Units (U) [dose–response curve]; (2) mean AshworthCBL per onabotulinumtoxinA dose depicting the responses seen with specific dose injection clusters/groups for each specific muscle group; and (3) onabotulinumtoxinA dose estimated to produce a mean 1‐point decrease in AshworthCBL as an indicator of clinically meaningful benefit of treatment. Increasing onabotulinumtoxinA doses produced greater AshworthCBLs (muscle tone improvements). The maximal week 6 response (Emax) model indicated a saturating dose–response relationship, with mean Emax AshworthCBL values of ‐1.48, ‐1.48, ‐0.63, ‐0.77, and ‐0.61 in the FCR, FCU, FDS, FDP, and BB, respectively. OnabotulinumtoxinA doses estimated to produce a mean 1‐point decrease in AshworthCBL were: 22.5U, 18.4U, 66.3U, 42.5U in the FCR, FCU, FDS, and FDP, respectively, and not determinable in the BB. These analyses demonstrate a saturating effect of greater muscle tone improvements with increasing onabotulinumtoxinA doses in post‐stroke spasticity patients. These findings suggest potentially effective onabotulinumtoxinA doses in selected muscle groups in this study population. © 2010 Movement Disorder Society.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Texas</li>
</region>
<settlement><li>Los Angeles</li>
</settlement>
<orgName><li>Université de Californie du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Yablon, Stuart A" sort="Yablon, Stuart A" uniqKey="Yablon S" first="Stuart A." last="Yablon">Stuart A. Yablon</name>
</region>
<name sortKey="Abu Hakra, Susan" sort="Abu Hakra, Susan" uniqKey="Abu Hakra S" first="Susan" last="Abu-Shakra">Susan Abu-Shakra</name>
<name sortKey="Beddingfield Iii, Frederick C" sort="Beddingfield Iii, Frederick C" uniqKey="Beddingfield Iii F" first="Frederick C." last="Beddingfield Iii">Frederick C. Beddingfield Iii</name>
<name sortKey="Beddingfield Iii, Frederick C" sort="Beddingfield Iii, Frederick C" uniqKey="Beddingfield Iii F" first="Frederick C." last="Beddingfield Iii">Frederick C. Beddingfield Iii</name>
<name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
<name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
<name sortKey="Garabedian Uffalo, Susan M" sort="Garabedian Uffalo, Susan M" uniqKey="Garabedian Uffalo S" first="Susan M." last="Garabedian-Ruffalo">Susan M. Garabedian-Ruffalo</name>
<name sortKey="Vandenburgh, Amanda M" sort="Vandenburgh, Amanda M" uniqKey="Vandenburgh A" first="Amanda M." last="Vandenburgh">Amanda M. Vandenburgh</name>
<name sortKey="Zhou, Jihao" sort="Zhou, Jihao" uniqKey="Zhou J" first="Jihao" last="Zhou">Jihao Zhou</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001689 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001689 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:1D12C53AFAFD0319789B7A043657DDB7B6BBBFA9 |texte= Dose response with onabotulinumtoxinA for post‐stroke spasticity: A pooled data analysis }}
This area was generated with Dilib version V0.6.23. |